BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

294 related articles for article (PubMed ID: 18940297)

  • 1. Usefulness of dobutamine-induced changes of the two-dimensional longitudinal deformation predict clinical and neurohumoral improvement in men after levosimendan treatment in acutely decompensated chronic heart failure.
    Paraskevaidis IA; Bistola V; Ikonomidis I; Parissis JT; Papadopoulos C; Filippatos G; Kremastinos DT
    Am J Cardiol; 2008 Nov; 102(9):1225-9. PubMed ID: 18940297
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Dobutamine-induced changes of left atrial two-dimensional deformation predict clinical and neurohumoral improvement after levosimendan treatment in patients with acutely decompensated chronic heart failure.
    Paraskevaidis IA; Ikonomidis I; Parissis J; Papadopoulos C; Stassinos V; Bistola V; Anastasiou-Nana M
    Int J Cardiol; 2012 May; 157(1):31-7. PubMed ID: 21176979
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Assessment of sustained effects of levosimendan and dobutamine on left ventricular systolic functions by using novel tissue Doppler derived indices in patients with advanced heart failure.
    Oner E; Erturk M; Birant A; Kurtar Mansıroglu A; Akturk IF; Karakurt H; Yalcin AA; Uzun F; Somuncu MU; Yildirim A
    Cardiol J; 2015; 22(1):87-93. PubMed ID: 24846511
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effects of levosimendan versus dobutamine on inflammatory and apoptotic pathways in acutely decompensated chronic heart failure.
    Adamopoulos S; Parissis JT; Iliodromitis EK; Paraskevaidis I; Tsiapras D; Farmakis D; Karatzas D; Gheorghiade M; Filippatos GS; Kremastinos DT
    Am J Cardiol; 2006 Jul; 98(1):102-6. PubMed ID: 16784930
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Levosimendan versus dobutamine in heart failure patients treated chronically with carvedilol.
    Duygu H; Turk U; Ozdogan O; Akyuz S; Kirilmaz B; Alioglu E; Gunduz R; Bozkaya YT; Turkoglu C; Payzin S
    Cardiovasc Ther; 2008; 26(3):182-8. PubMed ID: 18786088
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effects of levosimendan versus dobutamine on left atrial function in decompensated heart failure.
    Duman D; Palit F; Simsek E; Bilgehan K; Sacide A
    Can J Cardiol; 2009 Oct; 25(10):e353-6. PubMed ID: 19812809
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Multidimensional contractile reserve predicts adverse outcome in patients with severe systolic heart failure: a 4-year follow-up study.
    Paraskevaidis IA; Ikonomidis I; Simitsis P; Parissis J; Stasinos V; Makavos G; Lekakis J
    Eur J Heart Fail; 2017 Jul; 19(7):846-861. PubMed ID: 28220640
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Value of IGF-I levels in the evaluation of response to treatment with levosimendan in patients with severe heart failure.
    Işık S; Cetin M; Ciçekçioğlu H; Uçar O; Çetin ZG; Ozuğuz U; Bakır F; Berker D; Güler S
    Anadolu Kardiyol Derg; 2011 Sep; 11(6):523-9. PubMed ID: 21821501
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Plasma B-type natriuretic peptide reduction predicts long-term response to levosimendan therapy in acutely decompensated chronic heart failure.
    Farmakis D; Parissis JT; Bistola V; Paraskevaidis IA; Iliodromitis EK; Filippatos G; Kremastinos DT
    Int J Cardiol; 2010 Feb; 139(1):75-9. PubMed ID: 18973957
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effect of levosimendan on E/E' ratio in patients with ischemic heart failure.
    Duygu H; Ozerkan F; Nalbantgil S; Zoghi M; Akilli A; Akin M; Nazli C; Ergene O
    Int J Cardiol; 2008 Jan; 123(2):201-3. PubMed ID: 17316845
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Levosimendan vs dobutamine for patients with acute decompensated heart failure: the SURVIVE Randomized Trial.
    Mebazaa A; Nieminen MS; Packer M; Cohen-Solal A; Kleber FX; Pocock SJ; Thakkar R; Padley RJ; Põder P; Kivikko M;
    JAMA; 2007 May; 297(17):1883-91. PubMed ID: 17473298
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Regional myocardial contractile reserve assessed by strain echocardiography and the response to cardiac resynchronization therapy.
    Mitro P; Murin P; Valocik G; Simurda M
    Cardiol J; 2014; 21(5):524-31. PubMed ID: 24526506
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effect of levosimendan on ventricular arrhythmias and prognostic autonomic indexes in patients with decompensated advanced heart failure secondary to ischemic or dilated cardiomyopathy.
    Flevari P; Parissis JT; Leftheriotis D; Panou F; Kourea K; Kremastinos DT
    Am J Cardiol; 2006 Dec; 98(12):1641-5. PubMed ID: 17145226
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Intravenous levosimendan vs. dobutamine in acute decompensated heart failure patients on beta-blockers.
    Bergh CH; Andersson B; Dahlström U; Forfang K; Kivikko M; Sarapohja T; Ullman B; Wikström G
    Eur J Heart Fail; 2010 Apr; 12(4):404-10. PubMed ID: 20335355
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The predictive value of QRS duration in response to levosimendan therapy in patients with decompensated heart failure.
    Cetin M; Uçar O; Cicekçioğlu H; Güven Cetin Z; Sahin M; Vasfi Ulusoy F; Aydoğdu S
    Acta Cardiol; 2012 Jun; 67(3):317-23. PubMed ID: 22870740
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [The effect of levosimendan and dobutamine treatment on QT dispersion in patients with decompensated heart failure: a prospective study].
    Paksoy F; Ulaş T; Tursun I; Dal MS; Oztekin E; Borlu F
    Anadolu Kardiyol Derg; 2012 Feb; 12(1):16-22. PubMed ID: 22214738
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Levosimendan allows detection of contractile reserve in patients with chronic ischaemic left ventricular dysfunction and non-diagnostic dobutamine echocardiography.
    Cianfrocca C; Pelliccia F; Auriti A; Guido V; Pasceri V; Li X; Richichi G; Mercuro G; Santini M
    Eur J Heart Fail; 2007 Sep; 9(9):897-900. PubMed ID: 17572145
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Short-term effect of levosimendan on free light chain kappa and lambda levels in patients with decompensated chronic heart failure.
    Kurt IH; Yavuzer K; Batur MK
    Heart Vessels; 2010 Sep; 25(5):392-9. PubMed ID: 20676961
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Duration of the beneficial effects of levosimendan in decompensated heart failure as measured by echocardiographic indices and B-type natriuretic peptide.
    McLean AS; Huang SJ; Nalos M; Ting I
    J Cardiovasc Pharmacol; 2005 Dec; 46(6):830-5. PubMed ID: 16306809
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Levosimendan in cardiac failure after subarachnoid hemorrhage.
    Busani S; Rinaldi L; Severino C; Cobelli M; Pasetto A; Girardis M
    J Trauma; 2010 May; 68(5):E108-10. PubMed ID: 20453750
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.